

INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

MEETING MINUTES

Meeting Date: Tuesday, September 30, 2025
Time: 12:00 pm Eastern Time
Location: Zoom Teleconference
Institution: Hackensack Meridian Health, Hackensack, NJ
Principal Investigator: Andrew Pecora, MD
Protocol: TuHURA Biosciences, Inc., MCC 2021-01
NCT Number: NCT06947928
Meeting Type: Continuing Review of Protocol and Site
Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of IFX-HU2.0 as an Adjunctive Therapy to Pembrolizumab in Checkpoint Inhibitor Naïve Subjects with Advanced or Metastatic Merkel Cell Carcinoma

1. Call to order:

The Meeting was called to order at 12:25 pm Eastern Time.

2. Introductions and orientation:

Introductions were made and the Chair oriented members to the meeting procedures.

3. Declaration of quorum:

Five voting members were present, including one local member unaffiliated with the institution and the Institution's Biosafety Officer. Also present were one Institutional Representative and IBC Services staff. The Chair declared that a quorum was present.

4. Conflict of Interest:

The Chair requested that voting members report any conflict of interest regarding this meeting. No conflicts of interest were reported.

5. Public posting:

The Biosafety Officer confirmed that notice of the meeting was publicly posted. No public comments were received by the site or the Committee regarding this review.

6. Approval of previous meeting minutes:

Minutes Approved - YES: 5 NO: 0 ABSTAIN: 0

7. Review of proposed research:

The Chair provided an overview of the protocol and status of the study.

The Chair provided an overview of changes since the last review.

8. Determination for biosafety level and period of IBC oversight:

The Committee previously determined that **BSL-1 containment facilities and practices plus Standard Precautions** are required for IFx-Hu2.0 since it consists of a DNA plasmid administered in a clinical setting. The Committee reaffirmed this determination.

The Committee previously determined that IBC oversight will continue for **3 months after the last subject's last dose of IFx- Hu2.0 locally**, provided that all biosafety criteria for study closure are also met. The Committee reaffirmed this determination.

9. Vote on the Protocol:

The Committee voted for the following determination on the Protocol:

X	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 5 NO: 0 ABSTAIN: 0

INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

10. Review of proposed facilities and practices:

The Chair provided an overview of the arrangement for the facilities and practices.

Point of Discussion:

1. The Committee had no questions or concerns regarding the proposed facilities and practices.

11. Site requirements:

The Chair reviewed training and communication requirements for maintaining IBC approval with the Biosafety Officer.

12. Vote on the Site:

The Committee voted for the following determination on the Site:

X	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 5

NO: 0

ABSTAIN: 0

13. Advice to the Institution: None.

14. Meeting adjourned: The meeting was adjourned at 12:30 pm Eastern Time.